Table 4.

Description of healthcare resource utilization during the observation period after ceritinib initiation.

Healthcare resource utilization, per patient per six months	Ceritinib patients (N = 164)
IP admissions, N (%)	1.1 ± 1.9 [0.0]
Patients with ≥1 IP admission	76 (46.3%)
IP days, mean ± SD [median]	10.3 ± 26.1 [0.0]
Days with DME services, mean ± SD [median]	1.2 ± 3.4 [0.0]
Days with EC services, mean ± SD [median]	0.8 ± 1.8 [0.0]
Days with OP services, mean ± SD [median]	23.4 ± 14.3 [21.2]
Home care services	3.4 ± 11.3 [0.0]
Skilled nursing facility services	0.7 ± 3.0 [0.0]
Office visits	18.3 ± 10.8 [16.3]
Ambulatory surgical centre visits	0.1 ± 0.6 [0.0]
Other OP services	0.9 ± 2.3 [0.0]
Days with drug administration-related claims	3.7 ± 5.5 [1.7]
Days with laboratory tests	6.6 ± 5.5 [6.1]

DME: durable medical equipment; EC: emergency care; IP: inpatient; OP: outpatient; SD: standard deviation.